araag2/HINT huggingface dataset:
Clinical trial NCT02691494 (phase 3, status: completed)
Conditions: uterine fibroids, heavy menstrual bleeding
ICD codes: G43.831, G43.839, G43.821, G43.829, N94.9, N94.89
Drugs: elagolix, placebo for estradiol/norethindrone acetate, estradiol/norethindrone acetate, placebo for elagolix
SMILES: COC1=C(F)C(=CC=C1)C1=C(C)N(CC2=C(C=CC=C2F)C(F)(F)F)C(=O)N(C[C@H](NCCCC(O)=O)C2=CC=CC=C2)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject is a premenopausal female at the time of Screening.

          -  Subject has a diagnosis of uterine fibroids documented by a pelvic ultrasound
             (transabdominal ultrasound/transvaginal ultrasound).

          -  Subject has heavy menstrual bleeding associated with uterine fibroids as evidenced by
             menstrual blood loss > 80 mL during each of two screening menses as measured by the
             alkaline hematin method.

          -  Subject has negative urine and/or serum pregnancy test in Screening and just prior to
             first dose.

          -  Subject has an adequate endometrial biopsy performed during Screening, the results of
             which show no clinically significant endometrial pathology.

        Exclusion Criteria:

          -  Subject has screening pelvic ultrasound or saline infusion sonohysterography results
             that show a clinically significant gynecological disorder.

          -  Subject has history of osteoporosis or other metabolic bone disease.

          -  Subject has clinically significant abnormalities in clinical chemistry, hematology, or
             urinalysis.

          -  Subject has a history of major depression or post-traumatic stress disorder (PTSD)
             within 2 years of screening, OR a history of other major psychiatric disorder at any
             time (e.g., schizophrenia, bipolar disorder).

          -  Subject is using any systemic corticosteroids for over 14 days within 3 months prior
             to Screening or is likely to require treatment with systemic corticosteroids during
             the course of the study. Over the counter and prescription topical, inhaled,
             intranasal or injectable (for occasional use) corticosteroids are allowed.
Clinical trial NCT02692703 (phase 3, status: completed)
Conditions: chronic hepatitis c, hcv, hepatitis c virus
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4, B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: glecaprevir/pibrentasvir
SMILES: [H][C@](C)(OC)[C@]([H])(N=C(O)OC)C(=O)N1CCC[C@@]1([H])C1=NC2=C(N1)C=C(F)C(=C2)[C@@]1([H])CC[C@@]([H])(N1C1=CC(F)=C(N2CCC(CC2)C2=CC=C(F)C=C2)C(F)=C1)C1=CC2=C(NC(=N2)[C@]2([H])CCCN2C(=O)[C@@]([H])(N=C(O)OC)[C@@]([H])(C)OC)C=C1F
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, at least 18 years of age at time of screening.

          -  Screening laboratory result indicating hepatitis C virus (HCV) genotype 1-6 (GT1-6)
             infection.

          -  Subject is a recipient of a cadaveric or living donor liver transplant which was a
             consequence of HCV infection at least 3 months prior to screening Or subject received
             a cadaveric or living donor kidney at least 3 months before screening.

          -  Subjects must be documented as non-cirrhotic.

          -  Subject is currently taking a stable immunosuppression regimen based on tacrolimus,
             sirolimus, everolimus, mycophenolate mofetil (MMF), mycophenolic acid, azathioprine,
             and/or cyclosporine.

        Exclusion Criteria:

          -  Female subject who is pregnant, breastfeeding or is considering becoming pregnant
             during the study or for approximately 30 days after the last dose of study drug.

          -  Clinical history of fibrosing cholestatic hepatitis post-transplant.

          -  Re-transplantation of the liver or kidney.

          -  Steroid resistant rejection of the transplanted liver or kidney, or a history of
             rejection treated with high dose steroid within 3 months of screening.

          -  History of post-transplant complications related to hepatic or renal vasculature.
Clinical trial NCT02692716 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: semaglutide, placebo
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female diagnosed with type 2 diabetes

          -  Age at least 50 years at screening and presence of cardiovascular disease, or age at
             least 60 years at screening and presence of at least one cardiovascular risk factor

        Exclusion Criteria:

          -  Current or previous (within 90 days prior to screening) treatment with any GLP-1
             (glucagon-like peptide-1) receptor agonist, DPP-4 (dipeptidyl peptidase-4) inhibitor
             or pramlintide

          -  Family or personal history of multiple endocrine neoplasia type 2 (MEN 2) or medullary
             thyroid carcinoma (MTC)

          -  History of pancreatitis (acute or chronic)

          -  History of major surgical procedures involving the stomach potentially affecting
             absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy,
             gastric bypass surgery)

          -  Subjects presently classified as being in New York Heart Association (NYHA) Class IV
             heart failure

          -  Planned coronary, carotid or peripheral artery revascularisation known on the day of
             screening

          -  Any of the following: myocardial infarction, stroke or hospitalisation for unstable
             angina or transient ischaemic attack within the past 60 days prior to screening

          -  Chronic or intermittent hemodialysis or peritoneal dialysis or severe renal impairment
             (corresponding to eGFR (glomerular filtration rate, estimated) below 30 mL/min/1.73
             m^2)

          -  History or presence of malignant neoplasms within the last 5 years (except basal and
             squamous cell skin cancer and carcinoma in situ)
Clinical trial NCT02694328 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: alks 3831, olanzapine
SMILES: CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject has a body mass index (BMI) of 18.0-30.0 kg/m^2, inclusive, at Visit 1 and
             Visit 2

          -  Subject meets the DSM-5 criteria for a primary diagnosis of schizophrenia

          -  Subject is appropriate for outpatient treatment; has no hospitalizations for acute
             exacerbations of schizophrenia within 6 months before Visit 1

          -  Subject has maintained a stable body weight (change </= 5%) for at least 3 months
             prior to Visit 1 based on self-report

          -  Additional criteria may apply

        Exclusion Criteria:

          -  Subject has any of the following psychiatric conditions per DSM-5 criteria:

          -  Diagnosis of schizoaffective disorder or bipolar I or II disorder, or current,
             untreated or unstable major depressive disorder

          -  Clinically significant cognitive difficulties present within the past 2 years that
             could interfere with participation in the study

          -  Drug-induced or toxic psychosis

          -  Any other psychiatric condition that could interfere with participation in the study

          -  Subject poses a current suicide risk at Visit 1 or Visit 2 in the opinion of the
             investigator

          -  Subject has inflammatory bowel disease or any other gastrointestinal disorder
             associated with weight loss, anorexia nervosa, or binge eating disorder

          -  Additional criteria may apply
Clinical trial NCT02694978 (phase 3, status: completed)
Conditions: iron deficiency anemia
ICD codes: D50.9, D50.0, D50.8
Drugs: ferumoxytol, fcm
SMILES: COC1=CC=CC=C1OCC(O)CO, C[C@@H]1O[C@@H]1P(O)(O)=O
Eligibility criteria:

        Key Inclusion Criteria include:

          -  Participants with IDA and in whom IV iron treatment is indicated and defined as:

               -  Participants with documented hemoglobin <12.0 g per deciliter (dL) for females
                  and <14.0 g/dL for males within 60 days of dosing And

               -  Participants with documented transferrin saturation (TSAT) ≤20% or Ferritin ≤100
                  nanograms (ng) per mL within 60 days of dosing

          -  Documented history of unsatisfactory oral iron therapy or in whom oral iron cannot be
             tolerated, or for whom oral iron is considered medically inappropriate (as per oral
             iron history questionnaire)

          -  All participants (male and female) of childbearing potential who are sexually active
             who agree to routinely use adequate contraception from randomization throughout the
             duration of the study

        Key Exclusion Criteria include:

          -  Known hypersensitivity reaction to any component of ferumoxytol or FCM

          -  History of allergy to an IV iron

          -  History of multiple drug allergies

          -  Participants with dialysis-dependent chronic kidney disease

          -  Hemoglobin ≤7.0 g/dL

          -  Female participants who are pregnant, intend to become pregnant, are breastfeeding,
             have a positive serum/urine pregnancy test or not willing to use effective
             contraceptive precautions during the study (including females of childbearing
             potential who are partners of male participants)
Clinical trial NCT02696785 (phase 3, status: completed)
Conditions: spondyloarthritis
ICD codes: M45.A2, M45.A3, M45.A4, M45.A5, M45.A6, M45.A7, M45.A0
Drugs: ixekizumab, placebo, adalimumab
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, O
Eligibility criteria:

        Inclusion Criteria:

          -  Are ambulatory.

          -  Diagnosis of radiographic axial spondyloarthritis (rad-xSpA) with sacroiliitis defined
             radiographically according to the modified New York criteria.

          -  Participants have a history of back pain ≥3 months with age at onset <45 years.

          -  In the past had an inadequate response to at least 2 non-steroidal anti-inflammatory
             drugs (for duration 4 weeks) or cannot tolerate NSAIDS.

          -  If taking NSAIDS be on a stable dose for at least 2 weeks prior to randomization.

          -  Have a history of prior therapy for axSpa for at least 12 weeks prior to screening.

        Exclusion Criteria:

          -  Have total ankylosis of the spine.

          -  Have received any prior, or are currently receiving, treatment with biologics, tumor
             necrosis factor inhibitors or other immunomodulatory agents.

          -  Have recently received a live vaccine within 12 weeks or have had a vaccination with
             Bacillus Calmette-Guerin (BCG) within the past year.

          -  Have an ongoing or serious infection within the last 12 weeks or evidence of active
             tuberculosis.

          -  Have a compromised immune system.

          -  Have any other serious and/or uncontrolled diseases.

          -  Have either a current diagnosis or a recent history of malignant disease.

          -  Have had major surgery within 8 weeks of baseline, or will require surgery during the
             study.

          -  Are pregnant or breastfeeding.
Clinical trial NCT02696798 (phase 3, status: completed)
Conditions: spondyloarthritis
ICD codes: M45.A2, M45.A3, M45.A4, M45.A5, M45.A6, M45.A7, M45.A0
Drugs: ixekizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Are ambulatory.

          -  Have an established diagnosis of radiographic axial spondyloarthritis (rad-xSpA) with
             sacroiliitis defined radiographically according to the modified New York criteria.

          -  Participants have a history of back pain ≥3 months with age at onset <45 years.

          -  Have had prior treatment with at least 1 and not more than 2 TNF inhibitors.

          -  Must have had an inadequate response to 2 or more NSAIDs at the therapeutic dose range
             for a total duration of at least 4 weeks OR have a history of intolerance to NSAIDs.

          -  Have a history of prior therapy for axSpa for at least 12 weeks prior to screening.

        Exclusion Criteria:

          -  Have total ankylosis of the spine.

          -  Have never taken a TNF inhibitor medication or have taken more than 2.

          -  Have recently received a live vaccine within 12 weeks or have had a vaccination with
             Bacillus Calmette-Guerin (BCG) within the past year.

          -  Have an ongoing or serious infection within the last 12 weeks or evidence of active
             tuberculosis.

          -  Have a compromised immune system.

          -  Have any other serious and/or uncontrolled diseases.

          -  Have either a current diagnosis or a recent history of malignant disease.

          -  Have had major surgery within 8 weeks of baseline, or will require surgery during the
             study.

          -  Are pregnant or breastfeeding.
Clinical trial NCT02699385 (phase 3, status: terminated)
Conditions: gastroenteritis
ICD codes: K52.1, K52.81, A09, K52.9, K52.0, K52.89, K52.29
Drugs: domperidone, placebo
SMILES: ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=CC=CC=C34)CC1)C(=O)N2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    study prematurely terminated upon recommendation of idmc due to lack of efficacy.
  
Eligibility criteria:

        Inclusion Criteria:

          -  The participant presents with at least 3 episodes of non-bilious, non-bloody vomiting
             within the 24 hours prior to visiting the physician's office. The participant has at
             least 2 signs and symptoms other than vomiting consistent with acute gastroenteritis
             (AG) (example, fever, nausea, diarrhea, abdominal pain, bloating, or discomfort)
             within 3 hours prior to visiting the physician's office

          -  The participant has mild-to-moderate dehydration

          -  The participant had at least 1 episode of non-bloody diarrhea within the 24 hours
             prior to the visiting the physician's office

        Exclusion Criteria:

          -  The participant has severe dehydration or severe malnutrition

          -  The participant who has vomiting and clinical symptoms for longer than 72 hours prior
             to the baseline physician's office visit

          -  The participant needs intravenous (IV) fluid replacement

          -  The participant has chronic severe diarrhea, a previous history of Helicobacter pylori
             infection or received treatment for H. pylori-induced gastritis, active peptic ulcer,
             celiac disease, Crohn's disease, ulcerative colitis, eosinophilic esophagitis,
             malabsorption, short bowel syndrome, post-viral gastroparesis, cyclic vomiting
             syndrome, or previous gastrointestinal surgery

          -  The participant has upper respiratory symptoms such as cough, congestion, otitis media
             or pharyngitis
Clinical trial NCT02703961 (phase 3, status: unknown status)
Conditions: cervical cancer
ICD codes: M50.20, M50.21, M50.30, M50.31, M50.80, M50.81, M50.90
Drugs: concurrent chemotherapy with cisplatin, concurrent chemotherapy with docetaxel, adjuvant chemotherapy with cisplatin and docetaxel
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1, [H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Biopsy-proven, invasive squamous cell carcinoma, adenocarcinoma, or
             adenosquamouscarcinoma of the cervix

          2. FIGO clinical stage IB2-IIB with pelvic lymph node metastasis or FIGO clinical stage
             III-IVA with or without pelvic lymph node metastasis

          3. ECOG performance score 0-1

          4. The bone marrow, hepatic and renal function was normal at registration

          5. The patients signed informed consent

        Exclusion Criteria:

          1. clear cell and small cell neuroendocrine, sarcoma

          2. FIGO stage IVB

          3. Prior invasive malignancy

          4. Prior systemic chemotherapy

          5. Prior radiotherapy to the pelvis or abdomen

          6. Severe, active co-morbidity

          7. Women who are pregnant

          8. immunocompromised status
Clinical trial NCT02706847 (phase 3, status: active, not recruiting)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: upadacitinib, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of rheumatoid arthritis (RA) for≥ 3 months.

          -  Treated for ≥ 3 months with ≥ 1 bDMARD therapy, but continue to exhibit active RA or
             had to discontinue due to intolerability or toxicity, irrespective of treatment
             duration prior to the first dose of study drug.

          -  Participant has been receiving csDMARD therapy ≥ 3 months and on a stable dose for ≥ 4
             weeks prior to the first dose of study drug. The following csDMARDs are allowed:
             methotrexate (MTX), sulfasalazine, hydroxychloroquine, chloroquine, and leflunomide. A
             combination of up to two background csDMARDs is allowed except the combination of MTX
             and leflunomide.

          -  Meets both of the following criteria:

          -  ≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68 joint
             counts) at Screening and Baseline Visits.

          -  hsCRP ≥ 3mg/L at Screening Visit.

        Exclusion Criteria:

          -  Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to
             tofacitinib, baricitinib, and filgotinib).

          -  History of any arthritis with onset prior to age 17 years or current diagnosis of
             inflammatory joint disease other than RA (including but not limited to gout, systemic
             lupus erythematosus, psoriatic arthritis, axial spondyloarthritis including ankylosing
             spondylitis and non-radiographic axial spondyloarthritis, reactive arthritis, overlap
             connective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia
             [currently with active symptoms]). Current diagnosis of secondary Sjogren's Syndrome
             is permitted.
Clinical trial NCT02706951 (phase 3, status: active, not recruiting)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: methotrexate, upadacitinib, placebo upadacitinib, placebo methotrexate
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of RA for >= 3 months.

          -  Subjects must have been on oral or parenteral MTX therapy >= 3 months and on a stable
             dose for >= 4 weeks prior to first dose of study drug.

          -  Must have discontinued all conventional synthetic disease-modifying anti-rheumatic
             drugs (csDMARDs) (other than MTX) >= 4 weeks prior to first dose of study drug.

          -  Meets the following minimum disease activity criteria: >= 6 swollen joints (based on
             66 joint counts) and >= 6 tender joints (based on 68 joint counts) at Screening and
             Baseline Visits.

        Exclusion Criteria:

          -  Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to
             tofacitinib, baricitinib, and filgotinib).

          -  Prior exposure to any biological disease-modifying anti-rheumatic drugs (bDMARDs).

          -  Current diagnosis of inflammatory joint disease other than RA. Current diagnosis of
             secondary Sjogren's Syndrome is permitted.
Clinical trial NCT02709538 (phase 3, status: completed)
Conditions: perennial allergic rhinitis
ICD codes: D69.0, L50.0, B44.81, J30.89, J30.9, L20.84, H10.45
Drugs: gsp 301 ns, gsp 301 placebo ns ph 3.7, gsp 301 placebo ns ph 7.0
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Aged ≥12 years and older inclusive of either sex.

          2. Documented clinical history of PAR (for at least 2 years preceding the Screening Visit
             [Visit 1]) and exhibiting a documented positive skin prick test (wheal diameter at
             least 3 mm greater than negative diluent control wheal) to at least 1 allergen known
             to induce PAR. Documentation of a positive result within 12 months prior to the
             Screening Visit (Visit 1) is acceptable.

        Exclusion Criteria:

          1. Pregnant or lactating women.

          2. History of anaphylaxis and/or other severe local reaction(s) to skin testing.

          3. History of positive test for HIV, Hepatitis B or Hepatitis C infection.

          4. Documented evidence of acute or significant chronic sinusitis or chronic purulent
             postnasal drip.

          5. Subjects with an active pulmonary disorder or infection.

          6. Subjects with posterior subcapsular cataracts or glaucoma